{
  "docId": "019de076-6120-7265-9083-1f4de3ff0bf7",
  "docSlug": "b6cd6d5e2a349d701bc6db22946ed621",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 52 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 35,
  "pageCount": 52,
  "prevPage": 34,
  "nextPage": 36,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 24,
  "notes": "BOIN stands for Bayesian Optimal Interval design.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-6120-7265-9083-1f4de3ff0bf7/35",
  "deckHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7",
  "deckJsonHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7.json",
  "deckAnchorHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7#slide-35",
  "components": [
    {
      "bbox": {
        "h": 0.55,
        "w": 0.85,
        "x": 0.07,
        "y": 0.25
      },
      "kind": "diagram",
      "text": "Flow diagram showing patient counts across dose levels (200mg to 15mg) and trial stages (BOIN, Expansion, All-Treated, Response-Evaluable).",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f7a67fe3-d19c-4285-9d97-ea624ebc1bae",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.07,
        "y": 0.19
      },
      "kind": "paragraph",
      "text": "All-Treated Population (N = 93)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a1d0c004-cd26-482f-b467-d61b1d92396f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.85,
        "x": 0.07,
        "y": 0.082
      },
      "kind": "source-note",
      "text": "Data cut-off: 8 Aug 2023. BOIN, Bayesian optimal interval design; mg, milligram; NSCLC, non-small cell lung cancer; QD, once daily. a First response evaluation is pending for 27 patients...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0ffd40f7-b74e-4403-b378-9a9553f37463",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.07,
        "y": 0.11
      },
      "kind": "title",
      "text": "Cohort Accrual | ALKOVE-1 Phase 1 Dose-Escalation",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "738c027a-f967-456a-a387-0bedf03a6a8f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "process",
      "slug": null,
      "matchId": "3650a7ce-219c-4e1f-922f-22750d96becd",
      "evidence": "Flow diagram showing patient progression through clinical trial stages.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 40,
      "from": 29,
      "name": "Jobs To Be Done",
      "slug": "53-jobs-to-be-done",
      "bestFor": "Product innovation, market entry, competitive positioning",
      "matchId": "5bd43550-4e7b-49ae-9310-ece1e67e14d2",
      "evidence": "Slides 29-40 present preclinical and clinical trial results for NVL-655.",
      "position": 1,
      "objective": "How can Nuvalent's therapies address the needs of patients with specific cancer mutations?",
      "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
      "confidence": 0.6,
      "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}